MDCO, an ophthalmic medical device company headquartered in Hangzhou, has reportedly secured nearly RMB 200 million in a Series B financing round. The funding was led by Hangzhou Qiantang Heda Bio-medical Investment Fund, Sunland Capital, and existing investor Decheng Capital. The capital raised will be allocated to bolster the company’s pipeline regulatory filings and enhance market promotion efforts.
MDCO’s product portfolio includes the myopia refractive lens MPL, cataract intraocular lens IOL, and the myopia correction defocusing lens, all of which have been successfully launched in the market, showcasing the company’s commitment to advancing ophthalmic care solutions. – Flcube.com
